Emerging antibiotic resistance against carbapenems is a serious issue and urgent measures are required to curb such development of resistance. There is paucity of data on the prevalence of carbapenem resistance in the Indian literature. This study involves a retrospective analysis of culture and sensitivity data on 174 clinical specimens obtained from different hospitals in Kanpur. Of the specimens, 15% grew bacilli which were resistant to at least one of the carbapenems. Of these bacilli 92% were resistant to Meropenem and sensitive to Imipenem. Only one specimen, that of urine grew E-coli which was resistant to Imipenem but sensitive to Meropenem. Staphylococcus aureus constituted majority (77%) of the resistant bacilli. E-coli were the second most common resistant bacilli to be isolated. Pseudomonas aeruginosa constituted 8% (2) of the resistant bacilli. Mengiococcus isolated once from a cerebrospinal fluid specimen was sensitive to Imipenem but resistant to Meropenem. Of the E-coli isolates 3% (3) were resistant. Results indicate alarming increase in the incidence of carbapenem resistance.
Deshpande LM, Fritsche TR, Jones RN. Molecular epidemiology of selected multidrug-resistant bacteria: A global report from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 2004;49:231-6.
Taneja N, Aharwal SM, Sharma M. Imipenem resistance in nonfermentors causing nosocomial urinary tract infections. Indian J Med Sci 2003;57:294-9
Finkelstein R, Rabina G, Kasis I, Mahamid I. Device-associated, device-day infection rates in an Israeli adult general intensive care unit. J Hosp Infect 2000;44:200-5.
Collec JG, Miles RS, Wan B. Tests for the identification of bacteria. In: Collee JG, Fraser AG, Marmion BP, Simmons A, editors. Mackie and McCartney Practical Medical Microbiology. 14th ed. Churchill Livingstone: Edinburg; 1996. p. 131-50.
National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility testing: 20th information supplement (M100-S12). NCCLS: Wayne PA; 2002.
Philippe E, Weiss M, Shultz JM, Yeomans F, Ehrenkranz NJ. Emergence of highly antibiotic-resistant Pseudomonas aeruginosa in relation to duration of empirical antipseudomonal antibiotic treatment. Clin Perform Qual Health Care 1999;7:83-7.
Baquero F, Negri MC, Morosini MI, Blazquez J. The antibiotic selective process: Concentration-specific amplification of low-level resistant populations. Ciba Found Symp 1997;207:93-111.
Tegeder I, Schmidtko A, Brautigam L, Kirschbaum A, Geisslinger G, Lotsch J. Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther 2002;71:325-33.
Verwaest C; Belgian Multicenter Study Group. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin Microbiol Infect 2000;6:294-302.
Ambler RP. The structure of beta-lactamases. Philos Trans R Soc London Bio Sci 1980;289:321-31.
Roopa Vishwanathan, MK Gupta. Meropenem resistance: An Alarming Sign!! 109th Research Meeting of The Medical Research Centre of Bombay Hospital held on 11th August 2003.
Babypadmini S, Appalaraju B. Extended spectrum beta-lactamases in urinary isolates of Escherichia coli and Klebsiella pneumoniae - Prevalence and susceptibility pattern in a tertiary care hospital. Indian J Med Microbiol 2004;22:172-4.